Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12185MR)

This product GTTS-WQ12185MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12185MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ15180MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ11848MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ1879MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ9166MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ11124MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ7316MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-144
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW